Nutex Health Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
NUTX$186.25-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited
| Six Months Ended June 30, | ||
|---|---|---|
| (In thousands) | 2026 | 2025 |
| Cash flows from operating activities: | ||
| Net income | $159,080 | $66,950 |
| Adjustment to reconcile net income to net cash from operating activities: | ||
| Depreciation and amortization | 10,809 | 10,340 |
| Stock-based compensation expense | (1,031) | 106,389 |
| Changes to deferred taxes | 1,775 | (4,865) |
| Debt accretion expense | 44 | 504 |
| Non-cash effect of change in estimate | (52,319) | — |
| Changes in operating assets and liabilities: | ||
| (Increase)/Decrease in Accounts receivable | (32,235) | (116,768) |
| (Increase)/Decrease in Accounts receivable - related party | 953 | (2,135) |
| (Increase)/Decrease in Inventories | (1,341) | 575 |
| (Increase)/Decrease in Prepaid expenses and other current assets | 4,122 | (8,640) |
| (Increase)/Decrease in Operating right-of-use assets | 805 | 121 |
| Increase/(Decrease) in Accounts payable | (4,067) | 19,334 |
| Increase/(Decrease) in Accounts payable - related party | 2,575 | 1,169 |
| Increase/(Decrease) in Operating lease liabilities | (728) | 194 |
| Increase/(Decrease) in Accrued arbitration expenses | 14,729 | 21,043 |
| Increase/(Decrease) in Accrued income tax expense | 3,139 | (18,169) |
| Increase/(Decrease) in Accrued expenses and other current liabilities | 3,408 | 2,180 |
| Net cash provided by operating activities | 109,718 | 78,222 |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (3,741) | (815) |
| Proceeds from restricted short-term investment | — | 2,941 |
| Cash related to asset acquisition | — | (1,994) |
| Net cash provided by (used in) investing activities | (3,741) | 132 |
| Six Months Ended June 30, | ||
|---|---|---|
| (In thousands) | 2026 | 2025 |
| Cash flows from financing activities: | ||
| Proceeds from lines of credit | — | 4,606 |
| Proceeds from notes payable | — | 258 |
| Repayments of lines of credit | (642) | (301) |
| Repayments of notes payable | (2,953) | (5,697) |
| Repayments of finance leases | (3,317) | (2,593) |
| Proceeds from exercise of warrants | 75 | — |
| Cash related to stock repurchases and retirements | (50,688) | — |
| Members' contributions | 1,405 | 242 |
| Members' distributions | (28,620) | (18,776) |
| Net cash used in financing activities | (84,740) | (22,261) |
| Net change in cash, cash equivalents, and restricted cash | 21,237 | 56,093 |
| Cash and cash equivalents - beginning of the period | 185,574 | 40,640 |
| Restricted cash - beginning of period | 297 | — |
| Cash and cash equivalents and restricted cash - beginning of period | 185,871 | 40,640 |
| Cash and cash equivalents - end of period | 205,208 | 96,733 |
| Restricted cash - end of period | 1,900 | — |
| Cash and cash equivalents and restricted cash - end of period | $207,108 | $96,733 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.